DA-125, a novel anthracycline derivative showing high-affinity DNA binding and topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway

被引:15
作者
Kim, SG [1 ]
Sung, M
Kang, KW
Kim, SH
Son, MH
Kim, WB
机构
[1] Seoul Natl Univ, Coll Pharm, Kwanak Gu, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Kwanak Gu, Seoul 151742, South Korea
[3] Dong A Pharmaceut Res Labs, Kyunggi Do 449900, South Korea
关键词
DA-125; chemotherapy; topoisomerase; JNK; apoptosis; DNA binding; doxorubicin;
D O I
10.1007/s002800100276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: DA-125[(8S, 10S)-8-(3-Aminopropa- noyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha -L-talopyranosyl) oxy]-7,8,9, 10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacene-dione hydrochloride] is a novel anthracycline derivative with anticancer activity. In the present study, we compared the cytotoxicity of DA-125 with that of doxorubicin in H4IIE rat hepatoma cells and investigated the mechanistic basis. Because activation of MAP kinases, in particular c-Jun N-terminal kinase (JNK), is implicated in apoptotic cell death, the signaling pathways responsible for DA-125-induced apoptosis were studied. Methods: Cytotoxicity and apoptosis were measured in H4IIE cells and cells were stably transfected with a dominant-negative mutant of JNK 1 (JNK1) by MTT and TUNEL assays. Inhibition of topoisomerase II activity was determined in vitro. Drug accumulation and DNA binding affinity were determined by fluorescence spectroscopy. Results: The cytotoxicity of DA-125 was greater than that of doxorubicin (IC50 11.5 vs 70 muM). DA-125 induced apoptosis with 30-fold greater potency than doxorubicin. Inhibition of topoisomerase II by DA-125 was fourfold greater. The presence of excess beta -alanine, a DA-125 moiety, failed to alter cytotoxicity and accumulation of DA-125, indicating that the improved cytotoxicity of DA-125 did not result from the p-alanine moiety. Greater cellular accumulation of DA-125 correlated with its high-affinity DNA binding. Although neither PD98059 nor SB203580 altered the degree of cytotoxicity induced by DA-125, JNK1 cells exhibited about a twofold greater viability than control cells. DA-125-indnced apoptosis was also decreased in JNK1(-)-transfected cells. Conclusions: DA-125 potently inhibited topoisomerase II activity and induced apoptosis by a high rate of prooxidant production. DA-125 exhibited high-affinity DNA binding with improved cellular drug accumulation. Apoptosis induced by DA125 involved the pathway of JNK1, but not ERK1/2 or p38 kinase.
引用
收藏
页码:511 / 518
页数:8
相关论文
共 25 条
[1]   Signalling pathways: Jack of all cascades [J].
Cahill, MA ;
Janknecht, R ;
Nordheim, A .
CURRENT BIOLOGY, 1996, 6 (01) :16-19
[2]   Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium [J].
Chuang, SM ;
Wang, IC ;
Yang, JL .
CARCINOGENESIS, 2000, 21 (07) :1423-1432
[3]  
DUVERNAY VH, 1980, CANCER RES, V40, P387
[4]  
Fritz G, 1999, MOL CELL BIOL, V19, P1768
[5]   Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes ΔΨm loss, caspase-9 activity, and apoptosis in Jurkat cells [J].
Gamen, S ;
Anel, A ;
Pérez-Galán, P ;
Lasierra, P ;
Johnson, D ;
Piñeiro, A ;
Naval, J .
EXPERIMENTAL CELL RESEARCH, 2000, 258 (01) :223-235
[6]   Topoisomerase poisoning activity of novel disaccharide anthracyclines [J].
Guano, F ;
Pourquier, P ;
Tinelli, S ;
Binaschi, M ;
Bigioni, M ;
Animati, F ;
Manzini, S ;
Zunino, F ;
Kohlhagen, G ;
Pommier, Y ;
Capranico, G .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :77-84
[7]  
Hayakawa K, 2000, ONCOL REP, V7, P267
[8]  
Hong WS, 1997, ANTICANCER RES, V17, P3613
[9]   Anti-apoptotic effect of quercetin: Intervention in the JNK- and ERK-mediated apoptotic pathways [J].
Ishikawa, Y ;
Kitamura, M .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1078-1087
[10]   Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling [J].
Jarvis, WD ;
Fornari, FA ;
Tombes, RM ;
Erukulla, RK ;
Bittman, R ;
Schwartz, GK ;
Dent, P ;
Grant, S .
MOLECULAR PHARMACOLOGY, 1998, 54 (05) :844-856